

**TRUSELTIQ  
(infigratinib)**

**Pre - PA Allowance**

None

---

**Prior-Approval Requirements**

**Age** 18 years of age or older

**Diagnosis**

Patient must have the following:

Unresectable locally advanced or metastatic cholangiocarcinoma

**AND ALL** of the following:

- a. Patient has had at least one prior therapy
- b. Fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test
- c. Baseline ophthalmological examination has been done and patient will be monitored for retinal pigment epithelial detachment (RPED)
- d. Prescriber agrees to monitor for hyperphosphatemia and agrees to withhold Truseltiq and initiate phosphate lowering therapy as clinically indicated
- e. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Truseltiq and for 1 month after the final dose
- f. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Truseltiq and for 1 month after the final dose

**Prior - Approval Limits**

**Quantity**

Medication	Daily Dosing Limits
Truseltiq 25 mg, 100 mg	125 mg per day

**Duration** 12 months

---

**Prior – Approval *Renewal* Requirements**

**TRUSELTIQ  
(infigratinib)**

**Age** 18 years of age or older

**Diagnosis**

Patient must have the following:

Unresectable locally advanced or metastatic cholangiocarcinoma

**AND ALL** of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Patient will be monitored for retinal pigment epithelial detachment (RPED)
- c. Prescriber agrees to monitor for hyperphosphatemia and agrees to withhold Truseltiq and initiate phosphate lowering therapy as clinically indicated
- d. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Truseltiq and for 1 month after the final dose
- e. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Truseltiq and for 1 month after the final dose

**Prior - Approval *Renewal* Limits**

Same as above